CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma. Wang Y, Chen J, Gao Y, Chai KXY, et al. Cancer Lett 2024;597:217080.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Wang Y, Chen J, Gao Y, Chai KXY, et al. CDK4/6 inhibition augments anti-tumor efficacy of XPO1 inhibitor selinexor in natural killer/T-cell lymphoma. Cancer Lett 2024;597:217080.
PMID: 38908542